OMS-906 is under clinical development by Omeros and currently in Phase II for Paroxysmal Nocturnal Hemoglobinuria. According to GlobalData, Phase II drugs for Paroxysmal Nocturnal Hemoglobinuria have a 93% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how OMS-906’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
OMS-906 is under development for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), complement 3 glomerulopathy (C3G), idiopathic immune complex-mediated glomerulonephritis (ICGN) and arthritis. It is administered through subcutaneous and intravenous routes. The drug candidate is a monoclonal antibody. It acts by targeting mannan-binding lectin serine protease 3 (MASP-3).
Omeros is a biopharmaceutical company that discovers, develops and commercializes small-molecule and protein therapeutics for large-market and orphan indications. The company’s marketed product, Omidria is a phenylephrine and ketorolac injection for use during cataract surgery or replacement of intraocular lens (IOL). The company is investigating its product candidates for the use in arthroscopic, ophthalmological, and other surgical procedures including thrombotic microangiopathies, mediated glomerulopathies, addictive and compulsive disorders among others. It is also evaluating preclinical product candidates for treatment of alternative pathway disorders, central nervous system disorders, metabolic, oncologic, musculoskeletal and other disorders. Omeros is headquartered in Seattle, Washington, the US.
For a complete picture of OMS-906’s drug-specific PTSR and LoA scores, buy the report here.